"Hit smart and early" - MS-Therapie mit Ozanimod

Detalles Bibliográficos
Autor principal: Ottenjann, Henrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Pharmaforum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088609/
http://dx.doi.org/10.1007/s15016-023-3073-2
_version_ 1785022603745820672
author Ottenjann, Henrike
author_facet Ottenjann, Henrike
author_sort Ottenjann, Henrike
collection PubMed
description
format Online
Article
Text
id pubmed-10088609
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-100886092023-04-12 "Hit smart and early" - MS-Therapie mit Ozanimod Ottenjann, Henrike NeuroTransmitter Pharmaforum Springer Medizin 2023-04-11 2023 /pmc/articles/PMC10088609/ http://dx.doi.org/10.1007/s15016-023-3073-2 Text en © Berufsverband Deutscher Nervenärzte e.V. (BVDN) 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Pharmaforum
Ottenjann, Henrike
"Hit smart and early" - MS-Therapie mit Ozanimod
title "Hit smart and early" - MS-Therapie mit Ozanimod
title_full "Hit smart and early" - MS-Therapie mit Ozanimod
title_fullStr "Hit smart and early" - MS-Therapie mit Ozanimod
title_full_unstemmed "Hit smart and early" - MS-Therapie mit Ozanimod
title_short "Hit smart and early" - MS-Therapie mit Ozanimod
title_sort "hit smart and early" - ms-therapie mit ozanimod
topic Pharmaforum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088609/
http://dx.doi.org/10.1007/s15016-023-3073-2
work_keys_str_mv AT ottenjannhenrike hitsmartandearlymstherapiemitozanimod

Ejemplares similares